Impact of extended-course oral nirmatrelvir/ritonavir in established Long COVID: a case series.
Cohen AK, Jaudon TW, Schurman EM, Kava L, Vogel JM, Haas-Godsil J, Lewis D, Crausman S, Leslie K, Bligh SC, Lizars G, Davids JD, Sran S, Peluso M, McCorkell L.
Cohen AK, et al.
Commun Med (Lond). 2025 Jan 6;4(1):261. doi: 10.1038/s43856-024-00668-8.
Commun Med (Lond). 2025.
PMID: 39762640